{"id":"614c7e410d4f","type":"article","url":"https://hartvaat.nl/2026/05/25/eas-consensus-familiaire-hypercholesterolemie-bij-kinderen-en-adolescenten/","title":"EAS-consensus: familiaire hypercholesterolemie bij kinderen en adolescenten","title_en":"Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog","huisarts","internist"],"tags":["eas-2026","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","vrouwen"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehag382","source_url":"https://doi.org/10.1093/eurheartj/ehag382","authors":["Albert Wiegman","Mafalda Bourbon","Tomas Freiberger","Samuel S Gidding","Susanne Greber-Platzer","Urh Groselj","Kirsten B Holven","Lisa C Hudgins","Steve E Humphries","Barbara A Hutten","Daiana Ibarretxe","Cristina Pederiva","Noel Peretti","Frederick J Raal","Uma Ramaswami","Veronika Sanin","Raul D Santos","Elisabeth Steinhagen-Thiessen","Gerald F Watts","Rosie Perkins","Marianne Benn","Christoph J Binder","Stefano Romeo","Jeanine E Roeters van Lennep"],"significance":9,"published":"2026-06-03","source_date":"2026-05-25","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/coronairlijden/esc-richtlijn-chronisch-coronairlijden-2024/"],"congress":"eas-2026","summary_en":"A new consensus statement from the European Atherosclerosis Society — led by Dutch authors (Wiegman, Amsterdam UMC; Roeters van Lennep, Erasmus MC) — urges every country to establish paediatric screening programmes, since current diagnostic criteria often miss children carrying an FH-causing variant. It presents revised diagnostic criteria and updated LDL-C goals, and stresses that lipid-lowering therapy in heterozygous FH should start before puberty — from age 6 if needed. With treatment algorithms for HeFH and HoFH and guidance on transition to adult care, the EAS aims to curb underdiagnosis and undertreatment.","created":"2026-07-03T10:32:15Z","updated":"2026-07-03T13:31:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een nieuwe consensusverklaring van de European Atherosclerosis Society — met Nederlandse hoofdauteurs (Wiegman, Amsterdam UMC; Roeters van Lennep, Erasmus MC) — pleit voor pediatrische screeningsprogramma's in alle landen, omdat de huidige diagnostische criteria kinderen met een ziekteveroorzakende FH-variant vaak missen. De verklaring presenteert herziene diagnostische criteria en aangescherpte LDL-C-streefwaarden, en benadrukt dat lipidenverlagende therapie bij heterozygote FH vóór de puberteit moet starten — zo nodig al vanaf 6 jaar. Met behandelalgoritmen voor HeFH en HoFH en aandacht voor een soepele overgang naar de volwassenenzorg wil de EAS onderdiagnose en onderbehandeling terugdringen.","abstract_original":"Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated LDL cholesterol (LDL-C) concentrations. FH exists in two forms: heterozygous FH (HeFH), which affects around 1 in 300 people worldwide, and homozygous FH (HoFH), which affects around 1 in 300 000. Individuals with FH are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD) and death, and those with HoFH are, if untreated, at extreme risk of ASCVD manifestations even before adulthood. Early diagnosis and treatment in childhood can extend or normalize life expectancy, but limited awareness, underdiagnosis, and undertreatment remain major challenges. This consensus statement aims to address these challenges, supported by increased knowledge of the pathogenesis of FH and the availability of an increasing range of lipid-lowering therapies (LLTs) that can be used from early ages. To increase the detection rate of FH, all countries are encouraged to establish a paediatric screening programme and, given that current diagnostic criteria often fail to identify children with an FH-causing genetic variant, revised diagnostic criteria are presented. Updated LDL-C treatment goals are proposed, and the importance of starting LLTs before puberty in children with HeFH, and, if needed, from 6 years, is highlighted. Guidance on how to manage FH is provided, including treatment algorithms for use in children with either HeFH or HoFH and a discussion on how to promote a smooth transition to adult care. Early detection and optimal treatment as advocated in this consensus statement are crucial to improving life expectancy for children and adolescents with FH."}